Autologous bone marrow mononuclear cells labeled with Tc-99m hexamethylpropylene amine oxime scintigraphy after intracoronary stem cell therapy in acute myocardial infarction
✍ Scribed by Claudio T. Mesquita; Patrícia L. Correa; Renata C. Felix; Jader C. Azevedo; Susana Alves; Cristina C. Oliveira; André Luiz S. Sousa; Radovan Borojevic; Hans Fernando R. Dohmann
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 102 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1071-3581
No coin nor oath required. For personal study only.
✦ Synopsis
Case presentation. A 57-year-old man admitted with acute myocardial infarction was submitted to primary angioplasty with intracoronary stent placement in an occluded left circumflex artery with an excellent final result. He agreed to participate in a bone marrow mononuclear cell-based therapy research protocol for acute myocardial infarction at our institution. Five days after the infarction, he received 1.0 ϫ 10 8 autologous bone marrow mononuclear (ABMMN) cell delivery in the left circumflex artery via a balloon catheter. Approximately 5% of these cells were labeled with technetium 99m (150 MBq) by incubation with hexamethylpropylene amine oxime (HMPAO). His perfusion images obtained on the third day after infarction via a nitrateenhanced Tc-99m tetrofosmin scan demonstrated severe hypoperfusion in the inferior and inferolateral walls (Figure 1, first, third and fifth rows). These perfusion images were compared with tomographic views of the chest obtained 8 hours after ABMMN-labeled cell delivery (Figure 1, second, fourth, and sixth rows), revealing intense accumulation of the ABMMN-labeled cells in the same infarcted area. Software coregistration of the images reveals the precise localization of the ABMMNlabeled cells in the infarcted area (Figure 2; perfusion, first row; ABMMN-labeled cells, second row; and fusion, third row). These findings suggest the engraftment of the ABMMN cells in the infarcted area, a prerequisite for the success of stem cell therapy.